32 Results for "

heterodimerization

" in MedChemExpress (MCE) Product Catalog:
Products (32)

32 Results for "heterodimerization" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-D0844
CAS No.: 27025-41-8
Synonyms: L-Glutathione oxidized; GSSG; Oxiglutatione
Glutathione oxidized (L-Glutathione oxidized) is produced by the oxidation of glutathione. Detoxification of reactive oxygen species is accompanied by production of glutathione oxidized. Glutathione oxidized can be used for the research of sickle cells and erythrocytes .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0527A
CAS No.: 549-18-8
Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0527
CAS No.: 50-48-6
Amitriptyline is an orally active tricyclic antidepressant (TCA). Amitriptyline mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline can reduce inflammation, angiogenesis and fibrosis. Amitriptyline binds to DAT (with Ki = 2.58 μM). Amitriptyline has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-110266
CAS No.: 1421448-26-1
Purity:  99.60%
Research Areas:  

Cancer

GN44028 is a potent and orally active hypoxia inducible factor (HIF)-1α inhibitor, with an IC50 of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization. GN44028 can be used in the research of cancers .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-116248
CAS No.: 144092-31-9
Purity:  98.97%
Target:  

RAR/RXR Apoptosis

Research Areas:  

Cancer

Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1420
CAS No.: 1446322-66-2
Research Areas:  

Cancer

TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99412
CAS No.: 2375835-91-7
Synonyms: OSE-127

Target:  

Interleukin Related

Research Areas:  

Cancer

Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18371
CAS No.: 1422955-31-4
Research Areas:  

Inflammation/Immunology

TC-S 7009 is a potent and selective HIF-2α inhibitor with a Kd of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α (Kd ? 5 μM). TC-S 7009 disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126316
CAS No.: 1708091-24-0
Purity:  98.16%
Target:  

FKBP

Research Areas:  

Others

Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .
loading...
    loading...
Cat. No.: HY-107413
CAS No.: 146670-40-8
Purity:  99.79%
Synonyms: BMS-649
Research Areas:  

Cancer

SR11237 (BMS-649) GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-159644
CAS No.: 2709069-30-5
Synonyms: AB521
Research Areas:  

Cancer

Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
loading...
    loading...
Cat. No.: HY-103689
CAS No.: 259886-51-6
Purity:  ≥98.0%
Research Areas:  

Others

Cucurbit[8]uril is a potent, low toxicity and orally active supramolecular inducer of protein heterodimerization. Cucurbit[8]uril induces heterodimerization of methylviologen and naphthalene functionalized proteins. Cucurbit[8]uril can induce energy transfer .
loading...
    loading...
Cat. No.: HY-128845
CAS No.: 2358775-70-7
Purity:  99.84%
Target:  

PROTACs E1/E2/E3 Enzyme

Research Areas:  

Cancer

PROTAC CRBN Degrader-1 (Compound 14a) is a VHL-CRBN heterodimerization PROTAC degrader that achieves a selective degradation of CRBN by binding two E3 ubiquitin ligases (VHL and CRBN) to each other .
loading...
    loading...
Cat. No.: HY-160053
Target:  

PDGFR

Research Areas:  

Cancer

Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
loading...
    loading...
Cat. No.: HY-112374
CAS No.: 2207-44-5
Purity:  98.29%
Research Areas:  

Neurological Disease

NPAS3-IN-1 is a potent inhibitor of NPAS3-ARNT heterodimerization and regulates NPAS3 transcription by disrupting the heterodimerization of NPAS3 with ARNT at the cellular level .
loading...
    loading...
Cat. No.: HY-149085
CAS No.: 346721-50-4
Purity:  98.67%
Target:  

RAR/RXR

Research Areas:  

Cancer

XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting pRXRα-PLK1 interaction. XS-060 inhibits p-RXRα interaction with PLK1 but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK1 at the centrosome .
loading...
    loading...
Cat. No.: HY-118998
CAS No.: 1603845-42-6
Target:  

PROTACs EGFR ERK Akt

Research Areas:  

Cancer

TX2-121-1 is a potent and selective Her3 (ErbB3) degrader that contains a hydrophobic adamantane moiety. TX2-121-1 has an IC50 of 49 nM for Her3. TX2-121-1 inhibits Her3-dependent signaling and heterodimerization of Her3. TX2-121-1 has the ability to inhibit cell proliferation. TX2-121-1 can be used in the study of tumors. (Pink: Her3 inhibitor (HY-164988); Black: Linker; Blue: Adamantane (HY-N2427)) .
loading...
    loading...
Cat. No.: HY-162793
Research Areas:  

Infection

RdRP-IN-8 (compound 45) is an anti-influenza virus compound. RdRP-IN-8 inhibits viral RNA-dependent RNA polymerase (RdRP) activity by disrupting heterodimerization of PA and PB1 subunits (EC50=0.13 μM) .
loading...
    loading...
Cat. No.: HY-P10812
CAS No.: 1631984-43-4
Target:  

Peptides

Research Areas:  

Cancer

CP61, a cyclic peptide, is a dual CtBP1/CtBP2 inhibitor. CP61 binds CtBP1 with 3 μM affinity. CP61 inhibits the heterodimerization and homodimerization of CtBP2 with an IC50 value of 19 μM. CP61 is promising for research of cancers .
loading...
    loading...
Cat. No.: HY-P1420A
Research Areas:  

Cancer

TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM .
loading...
    loading...